Wei Gao

发表

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development

T. Post, M. Rizk, F. Kesisoglou, 2021, CPT: pharmacometrics & systems pharmacology.

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

S. Bhagani, J. Butterton, J. Arribas, 2021, NEJM Evidence.

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection

N. Shire, R. Railkar, A. Webber, 2019, Clinical pharmacology and therapeutics.

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.

B. Payne, J. Butterton, C. Assaid, 2021, NEJM evidence.

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development

Youfang Cao, J. Stone, L. Caro, 2021, Clinical and translational science.

Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia

J. Fiedler-Kelly, Hwa-ping Feng, Zufei Zhang, 2020, Journal of clinical pharmacology.

Second-generation versus first-generation drug-eluting stents in saphenous vein graftdisease: A meta-analysis of randomized controlled trials.

Zheyong Huang, Hai-bo Liu, Lei-lei Ma, 2016, International journal of cardiology.

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

M. Kollef, A. Shorr, Elizabeth G. Rhee, 2021, Critical Care.

Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registry.

Ben He, W. Shen, Ya‐Ling Han, 2008, International journal of cardiology.

Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.

Ben He, G. Fu, Yundai Chen, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)

Elizabeth G. Rhee, Hwa-ping Feng, E. Jensen, 2020, Antimicrobial Agents and Chemotherapy.

Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia

Elizabeth G. Rhee, J. Fiedler-Kelly, Hwa-ping Feng, 2022, Journal of clinical pharmacology.

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Daniel S Spellman, Amy S. Espeseth, A. Espeseth, 2021, EBioMedicine.

Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection

E. Asante-Appiah, T. Hassanein, K. Kowdley, 2019, Journal of viral hepatitis.

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

M. Rizk, W. Holman, W. Painter, 2023, CPT: pharmacometrics & systems pharmacology.